{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:02Z","timestamp":1753891202924,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013277","name":"National Clinical Key Specialty Project Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To demonstrate that the demographic and treatment characteristics of retinopathy of prematurity (ROP) eyes showed different types of hyperfluorescence in fluorescein angiography (FA) initially treated with anti-vascular endothelial growth factor (VEGF) agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A consecutive case series of ROP treated with anti-VEGF agents was retrospectively studied. All the patients underwent FA examinations at least 6 months later after treatment. The demographic and treatment characteristics of eyes with or without hyperfluorescence in FA were analyzed. The different types of hyperfluorescence were divided into three groups, including vascular leakage, fibrous membrane, and vascular abnormality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and forty-two eyes of 123 patients with treatment-required ROP were included. Hyperfluorescence was defined in 51\/242 eyes, and 2.08 \u00b1 1.11 injections were performed for them, while the eyes without hyperfluorescence received 1.65 \u00b1 0.80 injections (<jats:italic>P<\/jats:italic> = 0.013). Vascular leakage was defined in 26\/51 hyperfluorescence eyes. The postmenstrual age (PMA) of first injection for the hyperfluorescence group was 38.56 \u00b1 3.24 weeks, which is earlier than that of infants without hyperfluorescence (<jats:italic>P<\/jats:italic> = 0.011). More additional treatments were performed in eyes with hyperfluorescence (23.53 vs. 3.66%, <jats:italic>P<\/jats:italic> = 0.000). Among them, the eyes with vascular leakage required more additional treatment than eyes without vascular leakage (42.31 vs. 4.00%, <jats:italic>P<\/jats:italic> = 0.004). For the 26 eyes with vascular leakage, 11 eyes of 8 patients received further treatments during further follow-up. No significant difference of refractive errors can be defined between different groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Eyes with persistent hyperfluorescencein FA after treatment required more anti-VEGF and additional treatments, including laser and PPV. Not all hyperfluorescences were vascular leakage and required additional treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.800821","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T04:35:53Z","timestamp":1642998953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Different Types of Hyperfluorescence Observed in Post Anti-VEGF Fluorescein Angiographic Patterns in Retinopathy of Prematurity Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Enzhong","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: areview of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina."},{"key":"B4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (vegf) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS ONE."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper C Wright","year":"2019","journal-title":"Retina."},{"key":"B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3928\/23258160-20161219-11","article-title":"Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity ophthalmic surg lasers imaging","volume":"48","author":"Day","year":"2017","journal-title":"Retina."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ophtha.2010.04.021","article-title":"Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity","volume":"118","author":"Lepore","year":"2011","journal-title":"Ophthalmology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3935945","DOI":"10.1155\/2019\/3935945","article-title":"Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity","volume":"2019","author":"Jin","year":"2019","journal-title":"J Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina."},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.800821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T04:35:56Z","timestamp":1642998956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.800821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":17,"alternative-id":["10.3389\/fmed.2021.800821"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.800821","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"article-number":"800821"}}